biotech · Parkinson Disease · Amyotrophic Lateral Sclerosis · DNLI
Denali Therapeutics
Denali Therapeutics trial registry — 28 ClinicalTrials.gov studies with program phase, status, and indication context.
161 Oyster Point Blvd, South San Francisco, California 94080, US HQ
2015 Founded
567 Employees
Public company Type
DNLI · NYSE Ticker
Company details
- Status
- Public
- HQ
- 161 Oyster Point Blvd, South San Francisco, California 94080, US
- Founded
- 2015
- Employees
- 567
- Programs
- 23
- Drugs
- 10
- Patents
- 42
Denali Therapeutics clinical trials
Registry index of 28 ClinicalTrials.gov studies linked to Denali Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Denali Therapeutics trial registry — 28 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Denali Therapeutics.
-
DNLI-H-0001 — Phase 2
Clinical update -
DNLI-K-0001 — Phase 1
Clinical update -
DNLI-E-0002 — Phase 2
Clinical update -
Elaprase 2 mg/ml concentrate for solution for infusion — Phase 3
Clinical update -
[14C] BIIB122 ([14C] DNL151) — Phase 1
Clinical update -
BIIB122, Placebo to BIIB122 — Phase 2
Clinical update -
DNL747 — Phase 1
Clinical update -
DNL628 — Phase 1
Clinical update
Trial registry
-
CTIS ↗ -
CTIS ↗ - 2024-510990-21-00CTIS ↗
Elaprase 2 mg/ml concentrate for solution for infusion
Mucopolysaccharidosis Type II [MPS II]
-
CTIS ↗ -
CTIS ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗